NASH Observatory

⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.

NASH Observatory Commented Articles

IL11 modulates hepatocyte metabolism

In this paper, J. Dong et al. (Duke-National University of Singapore Medical School, Singapore) investigate the role of IL11 in hepatocyte lipotoxicity. Their data show that IL11 modulates hepatocyte metabolism and suggests a mechanism for NAFLD to NASH transition....

ByDr. G. Bozet, MD
OnAugust 3, 2021

NASH Observatory Commented Articles Comorbidities Articles

CNS dysfunctions as extrahepatic manifestations of NAFLD/NASH

Increasing evidences suggest that a correlation exists between NAFLD/NASH and central nervous system diseases or dysfunctions such as depression, mild cognitive impairment, Alzheimer’s disease, and dementia. In this review, M. Colognesi et al. (University of Padova, Italy) summarise the main correlations...

ByDr. D. Beard
OnAugust 3, 2021

NASH Observatory Commented Articles Definitions Articles

NAFLD as a metabolic disease, a review

A systematic literature review to identify recent epidemiological, biomarker, genetic and clinical evidence that expands our understanding of NAFLD as a metabolic disorder was performed by B. Cariou et al. (Inserm, CNRS, France). It appears that here is a growing body of evidence on the links between NAFLD/NASH pathogenesis and mechanisms of metabolic dysfunction...

ByDr. G. Bozet, MD
OnJuly 29, 2021

NASH Observatory Commented Articles Definitions Articles

Imaging biomarkers of NAFLD, NASH, and fibrosis

Globally, liver biopsy remains the reference standard for staging NAFLD severity. To diagnose NAFLD and quantify liver fat, MRI proton density fat fraction may be more informative than liver biopsy. In this review, V. Ajmera and R. Loomba (University of California, USA) critically examine the use...

ByDr. D. Beard
OnJuly 29, 2021

Management Articles Commented Articles NASH Observatory Ppar Articles

Pharmacotherapy in NAFLD/NASH

This review by SL Attia et al. (University of Kentucky College of Medicine, USA) summarises emerging pharmacotherapies for the treatment of adult and paediatric NAFLD. Investigated pharmacotherapies include lanifibranor (IVA337), an indole sulfonamide PPAR agonist that activates....

ByDr. G. Bozet, MD
OnJuly 26, 2021

NASH Observatory Commented Articles Diagnosis Articles

NAFLD: no liver biopsy in 2/3 patients of a real-world cohort

Much of the current data on NAFLD are derived from biopsy-based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of NAFLD. The aim of this study was to determine patient factors predictive....

ByDr. D. Beard
OnJuly 26, 2021

NASH Observatory Commented Articles Epidemiology Articles

Ethnicity and diversity in NAFLD

Globally, the rise in prevalence of obesity and metabolic syndrome as a whole has been linked to increased access to processed foods, such as refined sugars and saturated fats. Consequently, NAFLD is on the rise in both developed and developing nations.
This review by MAT Han et al...

ByDr. G. Bozet, MD
OnJuly 21, 2021

NASH Observatory Commented Articles Pathophysiology Articles

Alterations in gut microbiota in NASH

NAFLD pathophysiology has been linked to lower microbial diversity and a weakened intestinal barrier, exposing the host to bacterial components and stimulating pathways of immune defence and inflammation via toll-like receptor signaling. Moreover, this activation of inflammation in hepatocytes induces progression from simple steatosis to NASH...

ByDr. D. Beard
OnJuly 21, 2021

NASH Observatory

NASH is Part of a Multi-System Disorder

Prof Sanyal, USA, reminds us that NAFLD is the most common liver disease and reviews the comorbidities associated with NAFLD, and particularly the association with cardiovascular disease.

ByProf. Arun Sanyal
OnJuly 15, 2021

Management Articles Commented Articles Comorbidities Articles NASH Observatory

European NAFLD guidelines: limitations when applied to T2D patients

G. Besutti et al. aimed to evaluate the feasibility and efficiency of a guidelines-compliant NAFLD assessment algorithm in patients with newly diagnosed type 2 diabetes. Consecutive patients newly diagnosed with T2D without coexisting liver disease or excessive alcohol consumption were enrolled. They were stratified...

ByDr. G. Bozet, MD
OnJuly 14, 2021

NASH Observatory Commented Articles Comorbidities Articles Diagnosis Articles

NAFLD in patients with schizophrenia: early detection should be conducted

ndividuals with schizophrenia have high levels of medical comorbidity and cardiovascular risk factors. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors. Nevertheless, little is known regarding NAFLD in patients with schizophrenia. A. Koreki et al. analysed the medical...

ByDr. D. Beard
OnJuly 14, 2021

NASH Observatory Commented Articles Comorbidities Articles

Pulmonary hypertension and incidence of NAFLD: a retrospective study

In this retrospective cohort study of 18,910 patients, M. S. Jördens et al. examine a potential association between pulmonary hypertension and NAFLD and liver cirrhosis in an outpatient cohort in Germany. Their data suggests that incidence rates of NAFLD of NAFLD are significantly higher among patients with pulmonary ...

ByDr. G. Bozet, MD
OnJuly 12, 2021